Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €116.85 EUR
Change Today -1.27 / -1.07%
Volume 103.0
BM8 On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 12:26 PM 05/28/15 All times are local (Market data is delayed by at least 15 minutes).

biomarin pharmaceutical inc (BM8) Snapshot

Open
€116.31
Previous Close
€118.12
Day High
€121.25
Day Low
€116.31
52 Week High
03/31/15 - €123.02
52 Week Low
07/18/14 - €40.91
Market Cap
18.7B
Average Volume 10 Days
187.1
EPS TTM
--
Shares Outstanding
160.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOMARIN PHARMACEUTICAL INC (BM8)

biomarin pharmaceutical inc (BM8) Details

BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), an inherited metabolic disease; Aldurazyme used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Firdapse, a form of 3,4-diaminopyridine used for the treatment of Lambert Myasthenic Syndrome, an autoimmune disease. The company also conducts clinical trials on several investigational product candidates for the treatment of various diseases, including drisapersen, an exon-51 skipping compound for the treatment of Duchenne muscular dystrophy (DMD); pegvaliase, an enzyme substitution therapy for the treatment of PKU; reveglucosidase alfa, an enzyme replacement therapy for Pompe disease; talazoparib, an orally available poly-ADP ribose polymerase inhibitor for cancer treatment; BMN 111, a peptide therapeutic for achondroplasia treatment; BMN 044, BMN 045, and BMN 053 for DMD treatment; and cerliponase alfa for the treatment of late infantile neuronal ceroid lipofuscinosis. In addition, it develops preclinical product candidates for genetic and other metabolic diseases, such as BMN 270 and BMN 250. The company serves specialty pharmacies and end-users, such as hospitals and foreign government agencies; and distributors and pharmaceutical wholesalers. S.A. BioMarin Pharmaceutical Inc. has a collaboration agreement with Genzyme Corporation; and an agreement with Merck Serono. The company was founded in 1996 and is headquartered in San Rafael, California.

1,681 Employees
Last Reported Date: 03/2/15
Founded in 1996

biomarin pharmaceutical inc (BM8) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $916.0K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $480.6K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $528.2K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $417.7K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $409.6K
Compensation as of Fiscal Year 2014.

biomarin pharmaceutical inc (BM8) Key Developments

BioMarin Pharmaceutical Mulls Acquisitions

BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN) is seeking acquisitions. A senior BioMarin executive said that the company does not view itself as an acquisition candidate, but rather a potential buyer to build-up its own pipeline.

BioMarin Pharmaceutical Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-13-2015 10:00 AM

BioMarin Pharmaceutical Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-13-2015 10:00 AM. Venue: Encore at the Wynn, 3131 S Las Vegas Blvd, Las Vegas, Nevada, United States. Speakers: Jean-Jacques Bienaime, Chief Executive Officer and Director.

BioMarin Pharmaceutical Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Revised Earnings Guidance for the Year Ending December 31, 2015

BioMarin Pharmaceutical Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. GAAP net loss was $67.5 million or $0.43 per basic and diluted share for the first quarter of 2015, compared to GAAP net loss of $38.1 million or $0.27 per diluted share for the first quarter of 2014. Total revenue was $203.3 million against $151.6 million last year. Loss from operations was $65.9 million against $26.5 million last year. Loss before income taxes was $74.7 million against $34.6 million last year. Non-GAAP net loss was $25.1 million or $0.16 per basic and diluted share for the first quarter of 2015, compared to non-GAAP net loss of $1.7 million or $0.01 per basic and diluted share for the first quarter of 2014. The increased non-GAAP net loss and GAAP net loss for the first quarter of 2015 compared to the first quarter of 2014 was primarily due to the increased operating expenses, partially offset by continued strong commercial launch of Vimizim. The company revised earnings guidance for the year ending December 31, 2015. The company expects total revenue in the range of $850 million to $880 million against previous guidance in the range of $840 million to $870 million. The company reaffirmed non-GAAP net loss in the range of $130 million to $170 million, GAAP net loss in the range of $360 million to $400 million and research and development expense in the range of $610 million to $640 million. The company expects interest expense of $35.3 million, depreciation expense of $38.4 million, amortization expense of $12.4 million, LBITDA in the range of $318.9 million to $358.9 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BM8:GR €116.85 EUR -1.27

BM8 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $59.82 USD -0.75
Incyte Corp $107.73 USD -0.19
Jazz Pharmaceuticals PLC $179.46 USD +0.04
Vertex Pharmaceuticals Inc $126.93 USD -0.87
View Industry Companies
 

Industry Analysis

BM8

Industry Average

Valuation BM8 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 25.0x
Price/Book 8.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 23.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOMARIN PHARMACEUTICAL INC, please visit www.bmrn.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.